Arsanis Granted Key Patents for ASN100 Covering Cross-Neutralizing S. aureus Toxin Antibodies
March 14 2018 - 8:00AM
Business Wire
Patents strengthen Company’s intellectual
property portfolio for its lead product candidate ASN100 which is
designed to uniquely address Staphylococcus aureus infections
Arsanis, Inc. (NASDAQ:ASNS), a clinical-stage biopharmaceutical
company focused on applying monoclonal antibody immunotherapies to
address serious infectious diseases, today announced that the
United States Patent and Trademark Office ("USPTO") issued U.S.
Patent No. 9914767 to the company. This patent broadly claims
composition of matter for antibodies that cross-neutralize
Staphylococcus aureus alpha hemolysin (Hla) and up to four
additional S. aureus leukocidins targeted by ASN-1, one of the two
antibodies in the company’s lead product candidate, ASN100. ASN100
is a combination of two fully human monoclonal antibodies (mAbs)
that together neutralize the six cytotoxins critical to S. aureus
pneumonia pathogenesis, including toxins that damage lung tissue
and destroy human immune cells. This patent grants intellectual
property protection in the United States through 2033.
“ASN100 is a first-in-class mAb therapeutic designed to
precisely disarm a clinically important pathogen without inducing
antibiotic resistance, a mechanism-of-action which underpins
Arsanis’ novel approach to anti-infective development,” said René
Russo, chief executive officer of Arsanis. “The cross-reactive
nature of the ASN100 antibodies enables them to bind and neutralize
multiple S. aureus toxins simultaneously, which we believe
significantly differentiates ASN100 from other development stage
mAbs that neutralize only a single toxin.”
“The USPTO granting of this important patent follows similar
patents for the composition-of-matter for these cross-reactive
antibodies, including patent grants issued by the European Patent
Office in 2015, and by the Japan Patent Office and IP Australia in
2017,” said Michael Gray, chief operating officer and chief
financial officer of Arsanis. “We plan to continue our efforts to
strengthen our intellectual property portfolio for ASN100 and our
other pipeline programs.”
About ASN100
ASN100 is a combination of two co-administered fully human
monoclonal antibodies (mAbs), ASN-1 and ASN-2, that together
neutralize the six cytotoxins critical to S. aureus pneumonia
pathogenesis. ASN-1 neutralizes alpha-hemolysin (Hla), a cytotoxin
that damages lung epithelial cells, and four leukocidins,
cytotoxins that destroy human immune cells: gamma-hemolysin AB
(HlgAB), gamma-hemolysin CB (HlgCB), Panton-Valentine leukocidin
(PVL), and leukocidin ED (LukED). ASN-2 neutralizes the fifth
leukocidin, LukGH, a particularly potent human cytotoxin also
responsible for the destruction of human immune cells. ASN100 is
currently being evaluated in a Phase 2 clinical trial for the
prevention of S. aureus pneumonia in high-risk, mechanically
ventilated patients, and has received Fast Track designation from
the U.S. Food and Drug Administration (FDA).
About Arsanis
Arsanis, Inc. is a clinical-stage biopharmaceutical company
focused on applying monoclonal antibody (mAb) immunotherapies to
address serious infectious diseases. A deep understanding of the
pathogenesis of infection, paired with access to some of the most
advanced mAb discovery techniques and platforms available today,
has positioned Arsanis to build and advance a pipeline of
novel mAbs with multiple mechanisms of action and high potency
against their intended targets. The company’s lead clinical
program, ASN100, is aimed at serious Staphylococcus
aureus infections and is being evaluated in a Phase 2 clinical
trial for the prevention of S. aureus pneumonia in
high-risk, mechanically ventilated patients. In addition to ASN100,
the Arsanis preclinical pipeline is comprised of mAbs targeting
multiple serious bacterial and viral pathogens, including
respiratory syncytial virus.
Arsanis is a U.S. company headquartered in Waltham,
Massachusetts, with European research and preclinical development
operations headquartered in Vienna, Austria (Arsanis
Biosciences GmbH).
For more information, please visit the Arsanis website at
www.arsanis.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180314005109/en/
Media:Ten Bridge CommunicationsKrystle Gibbs,
508-479-6358krystle@tenbridgecommunications.comorInvestors:Michael
Gray, 781-819-5201Chief Operating and Chief Financial
Officermike.gray@arsanis.com
Actelis Networks (NASDAQ:ASNS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Actelis Networks (NASDAQ:ASNS)
Historical Stock Chart
From Apr 2023 to Apr 2024